Core Viewpoint - Inhibikase Therapeutics, Inc. is advancing its lead product candidate IKT-001 towards a late-stage clinical trial for Pulmonary Arterial Hypertension (PAH) and reported financial results for Q3 2025, highlighting a significant increase in net loss and changes in cash position [1][4][3]. Financial Results - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $77.3 million, down from $97.5 million as of December 31, 2024 [3]. - The net loss for Q3 2025 was $11.9 million, or $0.13 per share, compared to a net loss of $5.8 million, or $0.65 per share in Q3 2024. For the nine months ended September 30, 2025, the net loss was $35.5 million, or $0.40 per share, compared to a net loss of $15.4 million, or $2.03 per share for the same period in 2024 [4][14]. - Research and development expenses for Q3 2025 were $7.6 million, up from $4.2 million in Q3 2024. For the nine months ended September 30, 2025, R&D expenses totaled $23.4 million, which included a non-cash write-off of in-process R&D of $7.4 million [5]. - Selling, general and administrative expenses for Q3 2025 were $5.6 million, compared to $1.6 million in Q3 2024. For the nine months ended September 30, 2025, these expenses were $16.8 million, which included $1.0 million in severance expenses [6]. Recent Developments - The company plans to initiate a Phase 2b clinical study of IKT-001 in PAH during Q4 2025, with the trial expected to involve approximately 150 participants [2][8]. - The proposed IMPROVE-PAH trial will be a multi-center, randomized, double-blind, placebo-controlled study, with a primary efficacy endpoint of change in pulmonary vascular resistance at Week 26 [8]. - Timothy Pigot has been appointed as the Chief Commercial and Strategy Officer [8]. - The company is scheduled to present at the Jefferies Global Healthcare Conference in London on November 17, 2025 [8].